EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine

Yeshin Kim iD, Dong Woo Kang iD, Geon Ha Kim iD, Ko Woon Kim iD, Hee-Jin Kim iD, Seunghee Na iD, Kee Hyung Park iD, Young Ho Park iD, Gihwan Byeon iD, Jeewon Suh iD, Joon Hyun Shin iD, YongSoo Shim iD und 17 weitere

Dementia and Neurocognitive Disorders · 2025 · 24 (1) · 1

DOI: 10.12779/dnd.2025.24.1.1 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Dementia and Neurocognitive Disorders, 2025. Verfasst von Yeshin Kim und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Korea. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Evidence-based Healthcare Collaborating Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose: This clinical practice guideline provides evidence-based recommendations for treatment of dementia, focusing on cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists for Alzheimer's disease (AD) and other types of dementia.

Methods

Using the Population, Intervention, Comparison, Outcomes (PICO) framework, we developed key clinical questions and conducted systematic literature reviews. A multidisciplinary panel of experts, organized by the Korean Dementia Association, evaluated randomized controlled trials and observational studies. Recommendations were graded for evidence quality and strength using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.

Results

Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson's disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements. Both drug classes showed favorable safety profiles with manageable side effects.

Conclusions

This guideline offers standardized, evidence-based pharmacologic recommendations for dementia management, with specific guidance on cholinesterase inhibitors and NMDA receptor antagonists. It aims to support clinical decision-making and improve patient outcomes in dementia care. Further updates will address emerging treatments, including amyloid-targeting therapies, to reflect advances in dementia management.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer DiseaseCholinesterase InhibitorsDementiaMemantinePractice Guidelines

Autor:innen und Institutionen

  • Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Korea.
  • Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
  • Department of Neurology, Jeonbuk National University Medical School and Hospital, Jeonju, Korea.
  • Department of Neurology, Hanyang University Hospital, College of Medicine, Hanyang University, Seoul, Korea.
  • Department of Neurology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.

ORCID-Profile: Yeshin Kim, Dong Woo Kang, Geon Ha Kim, Ko Woon Kim, Hee-Jin Kim, Seunghee Na, Kee Hyung Park, Young Ho Park, Gihwan Byeon, Jeewon Suh, Joon Hyun Shin, YongSoo Shim, YoungSoon Yang, Yoo Hyun Um, Seong-Il Oh, Sheng-Min Wang, Bora Yoon, Sun Min Lee, Juyoun Lee, Jin San Lee, Jae-Sung Lim, Young Hee Jung, Juhee Chin, Hyemin Jang, Miyoung Choi, Yun Jeong Hong, Hak Young Rhee, Jae-Won Jang

Förderung

  • National Evidence-based Healthcare Collaborating Agency

Zitieren

APA

Kim, Y., Kang, D. W., Kim, G. H., Kim, K. W., Kim, H. J., Na, S., Park, K. H., Park, Y. H., Byeon, G., Suh, J., Shin, J. H., Shim, Y., Yang, Y., Um, Y. H., Oh, S. I., Wang, S. M., Yoon, B., Lee, S. M., Lee, J., …, & Korean Dementia Association (2025). Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine. Dementia and Neurocognitive Disorders, 24(1), 1. https://doi.org/10.12779/dnd.2025.24.1.1

Vancouver

Kim Y, Kang DW, Kim GH, Kim KW, Kim HJ, Na S, et al. Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine. Dementia and Neurocognitive Disorders. 2025;24(1):1. doi:10.12779/dnd.2025.24.1.1

BibTeX
@article{Kim2025,
  author = {Kim, Yeshin and Kang, Dong Woo and Kim, Geon Ha and Kim, Ko Woon and Kim, Hee-Jin and Na, Seunghee and Park, Kee Hyung and Park, Young Ho and Byeon, Gihwan and Suh, Jeewon and Shin, Joon Hyun and Shim, YongSoo and Yang, YoungSoon and Um, Yoo Hyun and Oh, Seong-Il and Wang, Sheng-Min and Yoon, Bora and Lee, Sun Min and Lee, Juyoun and San Lee, Jin and Lim, Jae-Sung and Jung, Young Hee and Chin, Juhee and Jang, Hyemin and Choi, Miyoung and Hong, Yun Jeong and Rhee, Hak Young and Jang, Jae-Won and Korean Dementia Association, Korean Dementia Association},
  title = {Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine},
  journal = {Dementia and Neurocognitive Disorders},
  year = {2025},
  volume = {24},
  number = {1},
  pages = {1},
  doi = {10.12779/dnd.2025.24.1.1}
}
Kostenlos starten →